 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...117118119120121122123124125126127...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Trial primary completion date, Metastases: Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma (clinicaltrials.gov) - Aug 10, 2016
P2, N=5, Completed, Sponsor: University of Miami
Recruiting --> Completed | N=35 --> 5 | Trial primary completion date: May 2018 --> Jun 2016
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date: Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 10, 2016
P2, N=30, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Completed | N=35 --> 5 | Trial primary completion date: May 2018 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Aug 2016
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Aug 10, 2016
P1, N=25, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Aug 2016 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial: Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Aug 10, 2016
P1/2, N=33, Recruiting, Sponsor: Northwell Health
- ||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: AlloStim (clinicaltrials.gov) - Aug 10, 2016
P2/3, N=450, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
Active, not recruiting --> Completed Initiation date: Dec 2016 --> Dec 2017 | Trial primary completion date: Dec 2018 --> Dec 2019
- |||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Aug 9, 2016
P3, N=490, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Dec 2016 --> Dec 2017 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=180, Completed, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jan 2016
- ||| temuterkib (LY3214996) / Eli Lilly
New P1 trial, Combination therapy, Metastases: A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer (clinicaltrials.gov) - Aug 3, 2016
P1, N=136, Not yet recruiting, Sponsor: Eli Lilly and Company
- Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: PD 0332991 and Cetuximab in Patients With Incurable SCCHN (clinicaltrials.gov) - Jul 28, 2016
P1/2, N=72, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jan 2016 Trial primary completion date: Aug 2016 --> Aug 2017
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Phase classification, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Jul 28, 2016
P1b, N=22, Recruiting, Sponsor: Julie E. Bauman, MD, MPH
Trial primary completion date: Aug 2016 --> Aug 2017 Phase classification: P1 --> P1b
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, IO biomarker: Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 27, 2016
P1/2, N=30, Recruiting, Sponsor: Fuda Cancer Hospital, Guangzhou
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial, Metastases: Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab (clinicaltrials.gov) - Jul 27, 2016
P1, N=9, Completed, Sponsor: Centre Hospitalier Universitaire de Besancon
- || simlukafusp alfa (RG7461) / Roche, Herceptin (trastuzumab) / Roche
Trial primary completion date, Combination therapy: A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) (clinicaltrials.gov) - Jul 23, 2016
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1 --> P1b Trial primary completion date: Jun 2018 --> May 2017
- | prexasertib (ACR-368) / Acrivon Therap
Phase classification, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer (clinicaltrials.gov) - Jul 23, 2016
P1b, N=70, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jun 2018 --> May 2017 Phase classification: P1 --> P1b
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Enrollment closed, Metastases: Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab (clinicaltrials.gov) - Jul 23, 2016
P2, N=19, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
Phase classification: P1 --> P1b Completed --> Active, not recruiting
- | Imbruvica (ibrutinib) / AbbVie, J&J
Phase classification, Combination therapy, Metastases: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) - Jul 22, 2016
P1b/2, N=261, Recruiting, Sponsor: Pharmacyclics
Completed --> Active, not recruiting Phase classification: P1/2 --> P1b/2
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial completion, Enrollment change, Metastases: Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab (clinicaltrials.gov) - Jul 21, 2016
P2, N=19, Completed, Sponsor: Academic and Community Cancer Research United
Phase classification: P1/2 --> P1b/2 Active, not recruiting --> Completed | N=80 --> 19
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: SAKK 16/08: Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 20, 2016
P2, N=69, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed | N=80 --> 19 Trial primary completion date: Jun 2016 --> Jan 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, alisertib (MLN8237) / Puma
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: MLN8237 in Head and Neck Cancer (clinicaltrials.gov) - Jul 20, 2016
P1, N=9, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Jun 2016 --> Jan 2016 Completed --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Oct 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=140, Recruiting, Sponsor: Southwest Oncology Group
Completed --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Oct 2015 Trial primary completion date: Jun 2017 --> Oct 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN (clinicaltrials.gov) - Jul 19, 2016
P2, N=38, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Jun 2017 --> Oct 2017 Trial primary completion date: May 2016 --> Apr 2018
- |||| Opdivo (nivolumab) / BMS
Trial primary completion date, Metastases: Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (clinicaltrials.gov) - Jul 19, 2016
P3, N=360, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: May 2016 --> Apr 2018 Trial primary completion date: Oct 2016 --> Nov 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 19, 2016
P2, N=76, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2016 --> Nov 2015 Trial primary completion date: May 2016 --> Dec 2016
- || cixutumumab (IMC A12) / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial primary completion date: Preoperative Treatment With Cetuximab and/or IMC-A12 (clinicaltrials.gov) - Jul 19, 2016
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Oct 2016 --> Oct 2018
- ||| Piqray (alpelisib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Trial primary completion date: Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=62, Not yet recruiting, Sponsor: Julie E. Bauman, MD, MPH
Trial primary completion date: Oct 2016 --> Oct 2018 Initiation date: Sep 2015 --> Aug 2016 | Trial primary completion date: Sep 2018 --> Aug 2019
- | Xalkori (crizotinib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
New P2 trial, Metastases: Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (clinicaltrials.gov) - Jul 19, 2016
P2, N=152, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer (clinicaltrials.gov) - Jul 13, 2016
P2, N=45, Completed, Sponsor: AIDS Malignancy Consortium
Initiation date: Sep 2015 --> Aug 2016 | Trial primary completion date: Sep 2018 --> Aug 2019 Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, urelumab (BMS-663513) / BMS, Ono Pharma
Phase classification, Combination therapy, Metastases: Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Jul 12, 2016
P1b, N=104, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Phase classification: P1 --> P1b
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, LEAC-102 / Taiwan Bio
New P1/2 trial, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 11, 2016
P1/2, N=30, Not yet recruiting, Sponsor: Taiwan Leader Biotech Corp.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Phase classification, Enrollment change, Metastases: Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 7, 2016
P1, N=2, Active, not recruiting, Sponsor: Julie E. Bauman, MD, MPH
Phase classification: P1 --> P1b Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=42 --> 2
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Aliqopa (copanlisib) / Bayer
New P1/2 trial, Combination therapy, Metastases: COPAN-ORL06: Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (clinicaltrials.gov) - Jul 5, 2016
P1/2, N=32, Recruiting, Sponsor: UNICANCER
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 4, 2016
P2, N=58, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=42 --> 2 Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum (clinicaltrials.gov) - Jul 4, 2016
P2, N=238, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Piqray (alpelisib) / Novartis
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 1, 2016
P1/2, N=179, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> May 2016
- ||| Nanoplatin (demplatin pegraglumer) / NanoCarrier, Orient Europharma
New P1 trial, Combination therapy, Metastases: Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer (clinicaltrials.gov) - Jun 29, 2016
P1, N=55, Recruiting, Sponsor: Orient Europharma Co., Ltd.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes (clinicaltrials.gov) - Jun 18, 2016
P2, N=31, Completed, Sponsor: UNICANCER
Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> May 2016 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: INTERCEPTOR: Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin (clinicaltrials.gov) - Jun 16, 2016
P3, N=278, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Dec 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA (clinicaltrials.gov) - Jun 16, 2016
P2, N=37, Recruiting, Sponsor: Northwell Health
- | Stivarga (regorafenib) / Bayer
Phase classification, Combination therapy, Metastases: Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination (clinicaltrials.gov) - Jun 16, 2016
P1b, N=54, Recruiting, Sponsor: Bayer
Trial primary completion date: May 2016 --> Dec 2016 Phase classification: P1 --> P1b
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jun 11, 2016
P2, N=245, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Phase classification: P1 --> P1b Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Trial primary completion date, Metastases: AGMT_HNO_PN: Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck (clinicaltrials.gov) - Jun 10, 2016
P3, N=154, Not yet recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Active, not recruiting --> Completed Initiation date: Apr 2016 --> Aug 2016 | Trial primary completion date: Jun 2019 --> Sep 2021
- ||| lumretuzumab (RG7116) / Roche
Trial completion, Phase classification, Trial primary completion date, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jun 2, 2016
P1a/1b, N=184, Completed, Sponsor: Hoffmann-La Roche
Initiation date: Apr 2016 --> Aug 2016 | Trial primary completion date: Jun 2019 --> Sep 2021 Active, not recruiting --> Completed | Phase classification: P1 --> P1a/1b | Trial primary completion date: May 2016 --> Feb 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date: Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction (clinicaltrials.gov) - May 31, 2016
P2, N=65, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Active, not recruiting --> Completed | Phase classification: P1 --> P1a/1b | Trial primary completion date: May 2016 --> Feb 2016 Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Mar 2013
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Surgery: Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - May 31, 2016
P1/2, N=33, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Mar 2013 Recruiting --> Completed | N=45 --> 33
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN (clinicaltrials.gov) - May 26, 2016
P2, N=100, Active, not recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Recruiting --> Completed | N=45 --> 33 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) (clinicaltrials.gov) - May 21, 2016
P2, N=27, Active, not recruiting, Sponsor: Stanford University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: CEBIFOX: Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (clinicaltrials.gov) - May 19, 2016
P2, N=59, Active, not recruiting, Sponsor: Martin Schuler, Prof. Dr. med.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Oct 2016
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - May 16, 2016
P2, N=30, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2015 --> Oct 2016 Trial primary completion date: Aug 2016 --> Aug 2017
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - May 15, 2016
P3, N=490, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Jul 2018 --> Jan 2020
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) - May 13, 2016
P2, N=375, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Trial primary completion date: Jul 2018 --> Jan 2020 Trial primary completion date: Mar 2016 --> Jun 2016